Related Experiment Video
Updated: Jan 20, 2026

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis
Published on: September 20, 2024
Antimicrobial Treatment of Staphylococcus aureus in Patients With Cystic Fibrosis
Susanna Esposito1, Guido Pennoni2, Valeria Mencarini2
1Pediatric Clinic, Cystic Fibrosis Center of Umbria Region, Department of Surgical and Biomedical Sciences, Università degli Studi di Perugia, Perugia, Italy.
Abstract:
Staphylococcus aureus is a ubiquitous human commensal pathogen. It is commonly isolated in cystic fibrosis (CF) patients and is considered one of the main causes of the recurrent acute pulmonary infections and progressive decline in lung function that characterize this inherited life-threatening multisystem disorder. However, the true role of S. aureus in CF patients is not completely understood. The main aim of this narrative review is to discuss the present knowledge of the role of S. aureus in CF patients. Literature review showed that despite the fact that the availability and use of drugs effective against S. aureus have coincided with a significant improvement in the prognosis of lung disease in CF patients, clearly evidencing the importance of S. aureus therapy, how to use old and new drugs to obtain the maximal effectiveness has not been precisely defined. The most important problem remains that the high frequency with which S. aureus is carried in healthy subjects prevents the differentiation of simple colonization from infection. Moreover, although experts recommend antibiotic administration in CF patients with symptoms and in those with persistent detection of S. aureus, the best antibiotic approach has not been defined. All these problems are complicated by the evidence that the most effective antibiotic against methicillin-resistant S. aureus (MRSA) cannot be used in patients with CF with the same schedules used in patients without CF. Further studies are needed to solve these problems and to assure CF patients the highest level of care.
Insights
Staphylococcus aureus significantly impacts cystic fibrosis (CF) lung disease, but optimal antibiotic strategies remain undefined. Further research is crucial for effective S. aureus treatment in CF patients.
Area of Science:
- Medical Microbiology
- Pulmonology
- Infectious Diseases
Background:
- Staphylococcus aureus is a common pathogen in cystic fibrosis (CF) patients.
- It contributes to recurrent pulmonary infections and lung function decline in CF.
- The precise role and optimal management of S. aureus in CF are not fully understood.
Purpose of the Study:
- To review current knowledge on the role of Staphylococcus aureus in cystic fibrosis patients.
- To discuss challenges in S. aureus diagnosis and treatment in CF.
- To highlight the need for further research in optimizing S. aureus therapies for CF.
Main Methods:
- Narrative literature review.
- Analysis of existing studies on S. aureus in CF.
- Discussion of therapeutic challenges and future research directions.
Main Results:
- Antibiotic availability has improved CF prognosis, underscoring S. aureus's importance.
- Differentiating S. aureus colonization from infection is difficult.
- Optimal antibiotic regimens and use of specific agents like those against MRSA in CF are not well-defined.
Conclusions:
- Effective S. aureus therapy is vital for CF patients.
- Challenges in diagnosis and treatment require further investigation.
- Optimized therapeutic strategies are needed to improve care for CF patients with S. aureus infections.
More Related Videos
Related Concept Videos
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
Cystic Fibrosis: Management
Sinus disease and chronic...
Antimicrobial Effectiveness
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

